AB-205

BIOLOGICAL2 trials

Sponsors

Angiocrine Bioscience

Conditions

Hodgkin LymphomaNon Hodgkin LymphomaNon-hodgkin Lymphoma

Phase 1

Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

CompletedNCT03925935

Angiocrine BioscienceHodgkin Lymphoma, Non-hodgkin Lymphoma

Start: 2019-05-07End: 2021-11-08Updated: 2022-03-03

Phase 3

A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

TerminatedNCT05181540

Angiocrine BioscienceHodgkin Lymphoma, Non Hodgkin Lymphoma

Start: 2022-02-21End: 2025-01-31Updated: 2025-02-04

Related Papers

Decoding Transcription Factor Dependent Enhancer-Gene Regulatory Networks That Define Hematopoietic Niche Function

Blood2024-11-05

A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care (SOC) Versus Placebo Plus Standard of Care in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (E-CELERATE) (NCT05181540) - Trials in Progress

Blood2022-11-15